{"DataElement":{"publicId":"3179442","version":"1","preferredName":"Person Strong Cytochrome P450 3A4 Induction Inhibition Agent Eligibility Determination Ind-2","preferredDefinition":"the yes/no indicator whether a person has received an agent that strongly induces or inhibits human CYP3A4 Gene.","longName":"3179227v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3179227","version":"1","preferredName":"Person Strong Cytochrome P450 3A4 Induction Inhibition Agent Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services based on having received an agent that strongly induces or inhibits human CYP3A4 Gene.","longName":"2236731v1.0:3179225v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3179225","version":"1","preferredName":"Strong Cytochrome P450 3A4 Induction Inhibition Agent Eligibility Determination","preferredDefinition":"Having strength, power, or intensity greater than average or expected.:Induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), Cytochrome P450 3A4 is a 502-amino acid 57.3-kD membrane-bound ER heme-thiolate monooxygenase. CYP3A4 is involved in an NADPH-dependent electron transport pathway and phase I oxidative metabolism of carcinogens, steroids, fatty acids, and xenobiotics, as well as bioactivation of aflatoxin B(1) to a genotoxic derivative. Activity seems a key predictor of drug responsiveness and toxicity. (from LocusLink, Swiss-Prot, OMIM, and NCI):The act of bringing about something.:The interference with or prevention of an action or response even though the stimulus for that action or response is present.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):Criteria to determine eligibility of patients for medical care programs and services.","longName":"3179225v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strong","conceptCode":"C62223","definition":"Having strength, power, or intensity greater than average or expected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Cytochrome P450 3A4","conceptCode":"C17573","definition":"Cytochrome P450 3A4 (503 aa, ~57 kDa) is encoded by the human CYP3A4 gene. This protein is involved in the oxidation of steroids, fatty acids and xenobiotics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98800737-B920-738F-E040-BB89AD436509","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98800737-B931-738F-E040-BB89AD436509","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104893","version":"1","longName":"GOG-0230D","context":"NRG"}]}],"AlternateNames":[{"name":"3179227v1.0:2018257v1.0","type":"USED_BY","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PtRcvIndExclMedTC","type":"COG GDE Short Name","context":"COG"},{"name":"3179227v1.0:2018257v1.0","type":"USED_BY","context":"COG"},{"name":"3179227v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Is the patient on medications","type":"Preferred Question Text","description":"Is the patient on medications classified as strong inducers or inhibitors of CYP3A4?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has patient received any of these strong or moderate inhibitors of CYP3A4","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_2","type":"Alternate Question Text","description":"Is patient receiving CYP3A4 active agents","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Is patient currently receiving any of the indicated CYP3A4 inducers or inhibitors","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_3","type":"Alternate Question Text","description":"Is patient receiving indicated CYP3A4 agents","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_4","type":"Alternate Question Text","description":"Is patient receiving indicated CYP3A4/5 agents","url":null,"context":"COG"},{"name":"CRF TEXT3","type":"Alternate Question Text","description":"Is patient receiving or planned to receive indicated CYP3A4/5 agents (strong inhibitors or inducers)","url":null,"context":"NRG"},{"name":"COG_CRF_TEXT_5","type":"Alternate Question Text","description":"Has patient received any of the indicated agents within 7 days prior to enrollment","url":null,"context":"COG"},{"name":"COG_CRF_TEXT_6","type":"Alternate Question Text","description":"Is patient receiving indicated CYP3A/CYP3A4 agents","url":null,"context":"COG"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Is the patient using any moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil)?","url":null,"context":"CTEP"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Is patient receiving indicated CYP3A4/5 or UGT agents","url":null,"context":"COG"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Treatment with Strong Inhibitors or Inducers of CYP3A4","url":null,"context":"Alliance"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Treatment with P-gp and Strong CYP3A4 Inhibitors and/or Inducers","url":null,"context":"Alliance"},{"name":"Alliance text 3","type":"Alternate Question Text","description":"Has the patient received a strong CYP3A4 inhibitor within 14 days prior to registration?","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9893E444-1757-F2E2-E040-BB89AD436F6B","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-29","modifiedBy":"ZHWENDY","dateModified":"2023-11-01","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}